Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B2 | P19099 | 1/20 | 0.36 |
| ▸ | CTSK | P43235 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | PDE4A | P27815 | 1/20 | 0.31 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.31 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.31 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.31 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.30 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28915190 | 0.86 | — | — | |
| SCHEMBL14787332 | 0.75 | MEN1 (0.32) | MEN1CYP2C9KMT2APDE4APDE4B | |
| SCHEMBL459723 | 0.74 | — | — | |
| SCHEMBL22885170 | 0.74 | MEN1 (0.34) | MEN1CYP2C9KMT2ATRIM24TRIM33 | |
| SCHEMBL873172 | 0.74 | — | — | |
| SCHEMBL16475311 | 0.73 | MEN1 (0.31) | MEN1CYP2C9KMT2A | |
| SCHEMBL1543385 | 0.73 | CTSK (0.34) | CYP11B2CTSKTRIM24TRIM33 | |
| SCHEMBL21726292 | 0.73 | CTSK (0.34) | CYP11B2CTSKTRIM24TRIM33 | |
| SCHEMBL11070723 | 0.71 | MEN1 (0.30) | MEN1CYP2C9KMT2APDE4APDE4B | |
| SCHEMBL10432969 | 0.70 | CTSK (0.39) | CTSKMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 107 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2822934-A1 | PHENICOL ANTIBACTERIALS | Zoetis LLC (US) | 2015-01-14 | — | — | EP | claimed |
| WO-2013134061-A1 | PHENICOL ANTIBACTERIALS | ZOETIS LLC (US) | 2013-09-12 | — | — | WO | claimed |
| US-20250326764-A1 | INHIBITORS OF THE MENIN-MLL INTERACTION | VITAE PHARMACEUTICALS LLC (US) | 2025-10-23 | — | — | US | disclosed |
| US-12312359-B2 | Inhibitors of the menin-MLL interaction | VITAE PHARMACEUTICALS, LLC (US) | 2025-05-27 | — | — | US | disclosed |
| US-20240360114-A1 | FERROPTOSIS MODULATORS, PREPARATIONS, AND USES THEREOF | Sironax Ltd. (KY) | 2024-10-31 | — | — | US | disclosed |
| EP-4384493-A1 | FERROPTOSIS MODULATORS, PREPARATIONS, AND USES THEREOF | Sironax Ltd (KY) | 2024-06-19 | — | — | EP | disclosed |
| CN-118076581-A | Iron death modulators, their preparation and use | 维泰瑞隆有限公司 | 2024-05-24 | — | — | CN | disclosed |
| EP-3822274-B1 | SYNTHETIC INTERMEDIATES USEFUL FOR PREPARING SUBSTITUTED AMINOPURINE COMPOUNDS | SIGNAL PHARM LLC (US) | 2024-03-06 | — | — | EP | disclosed |
| CN-114315834-B | Imidazolone derivatives and their use in medicine | 成都百裕制药股份有限公司 | 2024-01-05 | — | — | CN | disclosed |
| EP-4015513-B1 | IRAK INHIBITOR AND PREPARATION METHOD THEREFOR AND USE THEREOF | SHANGHAI MEIYUE BIOTECH DEV CO LTD (CN) | 2023-11-01 | — | — | EP | disclosed |
| US-20230174541-A1 | INHIBITORS OF THE MENIN-MLL INTERACTION | VITAE PHARMACEUTICALS, LLC | 2023-06-08 | — | — | US | disclosed |
| US-7569600-B2 | Compounds and methods for the treatment of prevention of Flavivirus infections | VIROCHEM PHARMA INC. (CA) | 2009-08-04 | — | — | US | disclosed |
| US-7569600-B2 | Compounds and methods for the treatment of prevention of Flavivirus infections | VIROCHEM PHARMA INC. (CA) | 2009-08-04 | — | — | US | disclosed |
| US-7569600-B2 | Compounds and methods for the treatment of prevention of Flavivirus infections | VIROCHEM PHARMA INC. (CA) | 2009-08-04 | — | — | US | disclosed |
| CN-101218224-A | Compositions and methods for treating or preventing flavivirus infections | VIROCHEM PHARMA INC (CA) | 2008-07-09 | — | — | CN | disclosed |
| US-7329675-B2 | Substituted azabicyclic compounds | AVENTIS PHARMA LIMITED (GB) | 2008-02-12 | — | — | US | disclosed |
| US-7329675-B2 | Substituted azabicyclic compounds | AVENTIS PHARMA LIMITED (GB) | 2008-02-12 | — | — | US | disclosed |
| EP-1879879-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS | Virochem Pharma Inc. (CA) | 2008-01-23 | — | — | EP | disclosed |
| US-20060276533-A1 | Compounds and methods for the treatment or prevention of Flavivirus infections | VERTEX PHARMACEUTICALS (CANADA) INCORPORATED (CA) | 2006-12-07 | — | — | US | disclosed |
| WO-2006119646-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS | VIROCHEM PHARMA INC. (CA) | 2006-11-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230174541-A1 | INHIBITORS OF THE MENIN-MLL INTERACTION | MLLT1, MEN1, MLLT3 | CYP11B2 3547/4885CTSK 4586/4885MEN1 2/4885 |
| US-20240360114-A1 | FERROPTOSIS MODULATORS, PREPARATIONS, AND USES THEREOF | AIFM2, GPX1, GPX4 | CYP11B2 300/4885CTSK 1490/4885MEN1 3261/4885 |
| US-12312359-B2 | Inhibitors of the menin-MLL interaction | MLLT1, MEN1, MLLT3 | CYP11B2 3547/4885CTSK 4586/4885MEN1 2/4885 |
| US-20250326764-A1 | INHIBITORS OF THE MENIN-MLL INTERACTION | MLLT1, MEN1, MLLT3 | CYP11B2 3547/4885CTSK 4586/4885MEN1 2/4885 |
| US-20060276533-A1 | Compounds and methods for the treatment or prevention of Flavivirus infections | ZC3HAV1, YBX1, HAX1 | CYP11B2 754/4885CTSK 2306/4885MEN1 1088/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.